When to move up a dose on Mounjaro: a practical guide

You're four weeks in and wondering whether it's time, here's what your prescriber is actually looking at

Picture this: the pen you started a month ago is nearly empty, it lives in the fridge door alongside the milk, and you're expecting to move to the next strength automatically. Most people do. But your prescriber is weighing two things against each other, how well your system has adapted, and whether pushing higher right now serves you or just hurries you into side effects you didn't need to have.

The 2.5 mg starting pen is not designed to produce significant weight loss. Its job is to let your body adjust to tirzepatide, Mounjaro's active ingredient, with the least disruption. The therapeutic work starts as you move upward. So when a prescriber considers whether the moment has come to go higher, the first question is not "has the weight moved?" but "has this dose been tolerated well?"

Tolerability, in practice, means nausea, vomiting, diarrhoea or constipation that is mild, manageable and easing rather than persistent or severe. If those symptoms are still prominent at week four, the right move is almost always to hold the current dose for another four weeks rather than layer a higher dose on top of a system that hasn't settled. The NHS tirzepatide guidance makes clear that titration pace is a clinical judgement, not a fixed rule everyone follows identically.

You can read more about the specific considerations around moving to 5 mg Mounjaro if that's the step you're approaching.

The green lights: signals that a dose increase is likely appropriate

There is no single test, but experienced prescribers look for a cluster of signals. First, gastrointestinal side effects have either not appeared or have settled to background noise. Second, you have been at the current strength for at least four weeks, the minimum interval built into the licensed schedule. Third, appetite suppression is present but has perhaps plateaued in its effect on your eating patterns. Those three together are a reasonable picture of readiness.

Weight-loss rate on its own is not a reliable trigger. Some people lose meaningfully at 2.5 mg; others see little movement until 7.5 mg or beyond. The clinical programme that informed Mounjaro's UK licence (SURMOUNT-1, involving 2,539 adults with obesity) demonstrated that the greatest average reductions came at the higher doses, but individual variation was significant. That's the evidence base behind the titration schedule: a slow ascent gives the medicine space to work at each level before the dose is raised again.

If you're uncertain whether your current dose is doing its job or whether you're ready to go higher, you can find a detailed breakdown of when to up your Mounjaro dose and what prescribers are specifically looking for at that point. At nume, a real prescriber reviews your file before every repeat order, not software, not a checklist ticked automatically. Details on when going up to 5 mg is the right step cover that specific transition in more depth.

For context on what each strength is and does, the Mounjaro 5 mg page sets that out clearly.

The amber lights: when holding the current dose is the wiser choice

Prescribers sometimes describe the titration schedule as the minimum recommended pace, not the mandatory pace. Slowing down is a legitimate and common clinical decision. The situations where holding makes more sense than moving up include: ongoing nausea that hasn't clearly eased, recent illness or significant life disruption that has affected eating and hydration, or a clinical review that finds current dose progress is still good and the risks of pushing higher outweigh the benefit.

There is also a ceiling to consider. If you reach the highest dose you can tolerate and NICE's appraisal of tirzepatide (published as NICE TA1026) notes this explicitly, you have not lost at least 5% of your starting weight after six months, continuing treatment is something to discuss carefully with your prescriber. That threshold applies to the NHS pathway but it is also sound clinical reasoning for private patients.

One thing worth knowing: adjusting Mounjaro doses is not something to do on your own initiative. Skipping a strength, going back to a lower one after a break, or timing changes around travel without prescriber input all carry risks that a short conversation avoids. The num FAQs address some of the practical questions around this, and our clinical support team is available seven days a week for aftercare questions between reviews.

You can also explore how Mounjaro works overall or look at the treatment overview if you're still weighing up your options.

What this means at your next review

Every repeat order with nume triggers a clinical re-review. That's not paperwork, it's the moment your prescriber confirms whether the current dose is still appropriate, whether a step up is clinically suitable, or whether something in your history warrants a different conversation.

To make that review count, be honest about what the current dose has felt like. Describe the side effects accurately, not minimised, not dramatised. Note whether your appetite and eating patterns have changed. Mention anything that's shifted, a new medicine, a procedure coming up, changes in your routine. That information is what allows a prescriber to judge whether now is genuinely the right moment to increase, or whether another four weeks at this level will serve you better.

The cost of Mounjaro treatment across the titration journey, and what's included in a single transparent price, is set out on the Mounjaro treatment page. If you're ready to begin that conversation with a prescriber, you can start your free consultation and have your case reviewed the same day.